Bioinformatics Pharmaceuticals Small Molecule 
Drug Target Review
JUNE 11, 2025
Multimodal language models Generative AI models (GenAI) in the pharmaceutical field have reached the highest level of attention with the Nobel Prizes to Demis Hassabis and John Jumper for AlphaFold, which can predict protein structures. Traditional drug discovery data architecture is manual, messy, proprietary and inflexible.
Drug Target Review
MARCH 28, 2024
Between 2000 and 2020, approximately 30 percent of the newly introduced small molecule drugs were derived from natural products. In short, this hypothesis underscores the potential benefits of aligning pharmaceutical development more closely with nature. References Newman DJ, Cragg GM.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Practical Cheminformatics
JANUARY 8, 2024
While large pharmaceutical companies have data on thousands or even millions of compounds, this data is rarely shared due to intellectual property concerns. Data from 21 million molecules and more than 40,000 assays was securely combined into a multitask model. For classification models, the participants reported a median 2.5-7.5%
Elrig
APRIL 29, 2024
Harini Srinivasan is a Principal Scientific Associate at Serna Bio with over 10 years of research experience in academic institutions, health care organizations and pharmaceutical companies. With a background in Bioinformatics and Computational Biology, she has a keen interest in using technology to solve problems in healthcare and medicine.
Drug Target Review
SEPTEMBER 26, 2024
Cresset delivers software solutions and contract research expertise enabling companies around the world to accelerate their small molecule discovery processes efficiently and effectively. Customers include the pharmaceutical, biotechnology and agrochemical industries.
The Pharma Data
NOVEMBER 15, 2020
R&D collaboration building on Lead Pharma’s expertise in the discovery, design and optimization of small molecule treatments. Lead Pharma is a pharmaceutical company focusing on the discovery and development of innovative medicines for the treatment of immune diseases and cancer. About Lead Pharma.
The Pharma Data
JANUARY 10, 2021
I actually think neuroscience is going to heat up in 2021,” said Ben Zeskind , co-founder and CEO of Immuneering , which is using bioinformatics and computational biology to develop new drugs in this space, along with oncology and immuno-oncology. In a boone for Slonim’s research focus, the year 2020 has made this molecule a household name.
Expert insights. Personalized for you.
Let's personalize your content